TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02981888

Intervention type: RADIATION
Intervention: X-Ray
Description: X-ray of the abdomen will be performed to assess colonic transit

Intervention type: RADIATION
Intervention: X-Ray
Description: X-ray of the abdomen will be performed to assess colonic transit

Intervention type: RADIATION
Intervention: X-Ray
Description: X-ray of the abdomen will be performed to assess colonic transit
Study: NCT02455297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY80-6946)
Description: Starting dose 60 mg (dose reduction due to toxicities to 45 mg allowed). Administered in slow IV bolus on days 1, 8 and 15 of each 28 day cycle until disease progression or until another criterion is met for withdrawal from study treatment.
Study: NCT03795493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short-term diet and exercise intervention
Description: Participants assigned to the intervention group will perform both the diet and acute exercise interventions. The interventions will be applied prior to up to six chemotherapy cycles of a consistent protocol. The total number of treatments of a given protocol received prior to treatment conclusion is dependent on patient condition and oncologic care preferences.
Study: NCT02958865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 or Placebo
Description: Delivered orally for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 or Placebo
Description: Delivered orally for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 or Placebo
Description: Delivered orally for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-06651600 or Placebo
Description: Delivered orally for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 or Placebo
Description: Delivered orally for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 or Placebo
Description: Delivered orally for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 or Placebo
Description: Delivered orally for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-06700841 or Placebo
Description: Delivered orally for 8 weeks.
Study: NCT05684601

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Third molar surgery
Description: It was extracted one impacted mandibular third molar per patient with piezoelectric or rotating drills device
Study: NCT00756886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 40 mg QD 7 day continue after procedure for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
Study: NCT02958865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: Delivered orally for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Delivered orally for 24 weeks.
Study: NCT04303858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eciskafusp Alfa
Description: Participants will be administered eciskafusp alfa in different schedules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eciskafusp Alfa
Description: Participants will be administered eciskafusp alfa in different schedules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eciskafusp Alfa
Description: Participants will be administered eciskafusp alfa in different schedules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will be administered 1200 mg of atezolizumab once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will be administered 1200 mg of atezolizumab once every 3 weeks.
Study: NCT04153487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid Injectable Product
Description: Intermittent Intravenous Infusion of Ascorbic Acid (Vitamin C) 2.5 gm / 6 hours for 96 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo saline / 6 hours for 96 hours
Study: NCT00977210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXi4503
Description: OXi4503 will be administered weekly for 3 weeks followed by a week with no treatment. The starting dose will be 0.06 mg/m2 given as an intravenous infusion over 10 minutes.
Study: NCT04163107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib Injection
Description: All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
Study: NCT01885078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study: NCT03139058

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the hepatic fibrosis
Description: Evaluation of the hepatic fibrosis stage by a hepatological assessment (Clinical, biological and imaging)
Study: NCT01885078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study: NCT04313582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmartPrompt smartphone application
Description: The SmartPrompt is a smartphone application designed specifically for older adults with difficulties remembering to do daily tasks due to cognitive difficulties.
Study: NCT01885078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study: NCT03115476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ingenol disoxate gel 0.018%
Description: Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
Study: NCT01837355

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04378868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics, cefuroxime and metronidazole
Description: Patient receives antibiotics while waiting appendectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics, cefuroxime and metronidazole
Description: Patient receives antibiotics while waiting appendectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No antibiotics
Description: No antibiotics are given while waiting surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No antibiotics
Description: No antibiotics are given while waiting surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: urgent schedule
Description: Patients can wait up to 8 hours for surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: urgent schedule
Description: Patients can wait up to 8 hours for surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: less urgent schedule
Description: Patients can wait up to 24 hours for surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: less urgent schedule
Description: Patients can wait up to 24 hours for surgery.
Study: NCT01659060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanol-rich dark chocolate
Description: The primary objective of this pilot RCT is to test the feasibility of design methods and procedures for later use on a larger scale. The secondary objective is to examine the acute and chronic effect of dark chocolate on endothelial function and blood pressure, among healthy pregnant women.
Study: NCT03115476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ingenol disoxate gel 0.037%
Description: Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Vehicle to ingenol disoxate gel with no active ingredient
Study: NCT00424983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT01935297

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: endurance and resistance exercise 3x/week for 8 weeks
Study: NCT01659060

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Chocolate
Description: Placebo intervention
Study: NCT04405531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: task-oriented training (TOT)
Description: The study group received a TOT together with a conventional occupational therapy (COT). The study groups received a treatment for 20 sessions at a hospital setting.
Study: NCT00999089

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Coronary Artery Bypass
Description: Coronary artery bypass grafting with extracorporeal circulation and cardioplegic arrest

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Off-Pump Coronary Artery Bypass
Description: Coronary artery bypass grafting without extracorporeal circulation or global myocardial ischemia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pump-Assisted Coronary Artery Bypass
Description: Coronary artery bypass grafting with a beating but unloaded heart by using extracorporeal circulation
Study: NCT04405531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional occupational therapy (COT)
Description: The control group received only a COT program. The control groups received a treatment for 20 sessions at a hospital setting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional occupational therapy (COT)
Description: The control group received only a COT program. The control groups received a treatment for 20 sessions at a hospital setting.
Study: NCT00310388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine (INN), Ezogabine (USAN)
Description: Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patients receives between 600 and 1200 mg of retigabine per day. The duration will be until the completion of the trial, or until the patient withdraws from the trial.
Study: NCT03988608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag 25 mg
Description: film-coated tablets containing 25 mg of eltrombopag free acid in each tablet
Study: NCT02581566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Dexmedetomidine
Description: Addition of Intathecal Dexmedetomidine plus Intrathecal Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular Dexmedetomidine
Description: Addition of Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: Intrathecal Bupivacaine
Study: NCT01587573

Intervention type: OTHER
Intervention: saliva collection prior to clinically driven oral biopsy
Description: cell free saliva to be used to measure mRNA and proteins by PCR and ELISA
Study: NCT03212079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mycoach Smart Text
Description: Personalized text messages to you cellphone to help you become more active

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyCoach on Amazon Alexa
Description: This is an intelligent voice that you can communicate with via Amazon echo speaker
Study: NCT01247831

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Selective Laser Trabeculoplasty
Description: 100 spots with an energy of 0,8 mJ are applied over 360° of the trabecular meshwork of glaucoma patients with a Q-switched 532 nm frequency doubled neodymium YAG Laser.
Study: NCT05266547

Intervention type: DEVICE
Intervention: OCT guided coronary intervention
Description: patients were divided into two groups,on OCT guided coronary group and coronary angiography guided group

Intervention type: DEVICE
Intervention: OCT guided coronary intervention
Description: patients were divided into two groups,on OCT guided coronary group and coronary angiography guided group
Study: NCT01363102

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SOMS
Description: Apply a number to mobilization goal for patient
Study: NCT03157947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid Tool
Description: Subjects will be given an I-pad with the decision aid program on it. A member of the study team will enter some preliminary information, then the subject will be able to review the tool with his doctor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: baseline survey
Description: patients will be given baseline surveys to gather demographic information and readiness to make a decision regarding prostate cancer care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: follow-up surveys
Description: at 3, 6, 9, and 12 months patients will be given follow-up surveys regarding prostate cancer care
Study: NCT02347605

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine lozenge 4 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge 4 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenge
Study: NCT02272127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icotinib
Study: NCT02918448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training group
Description: The investigation was carried out over a period of 18 weeks, with 12 weeks dedicated to the RT program and 6 weeks allocated for measurements. Anthropometric, one repetition maximum tests (1RM), body composition, blood pressure (BP), dietary intake and blood sample measurements were performed in weeks 1-3, and 16-18. A supervised progressive RT program was performed between weeks 4-15 by the training group.
Study: NCT00431964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin 250 mg tablets
Description: * One (1) tablet three times weekly for patients who weigh 40-79 lbs~* Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablets
Description: * One (1) tablet three times weekly for patients who weigh 40-79 lbs~* Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs
Study: NCT00961038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (PulmoSphere, BAYQ3939)
Description: 32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (PulmoSphere, BAYQ3939)
Description: 48,75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
Study: NCT03317249

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: 12-lead electrocardiogram

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: 12-lead electrocardiogram

Intervention type: DIAGNOSTIC_TEST
Intervention: heart rate monitor
Description: 24-hour heart rate monitor used to calculate mean heart rate and heart rate variability

Intervention type: DIAGNOSTIC_TEST
Intervention: heart rate monitor
Description: 24-hour heart rate monitor used to calculate mean heart rate and heart rate variability

Intervention type: DIAGNOSTIC_TEST
Intervention: Autonomic Nervous System (ANS) Activity
Description: Heart Rate Variability (HRV) and Baroreflex sensitivity (BRS):~Resting and exercise HRV and BRS calculated from ECG, Dundee Step test and blood pressure measurements.

Intervention type: DIAGNOSTIC_TEST
Intervention: Autonomic Nervous System (ANS) Activity
Description: Heart Rate Variability (HRV) and Baroreflex sensitivity (BRS):~Resting and exercise HRV and BRS calculated from ECG, Dundee Step test and blood pressure measurements.

Intervention type: DIAGNOSTIC_TEST
Intervention: Haemodynamic variables
Description: Cardiac output (CO), stroke volume (SV) and systematic vascular resistance (SVR) will be assessed and calculated using a non-invasive, inert gas re-breathing technique whereby expired gases will be sampled and analysed alongside and blood pressure measurements.

Intervention type: DIAGNOSTIC_TEST
Intervention: Haemodynamic variables
Description: Cardiac output (CO), stroke volume (SV) and systematic vascular resistance (SVR) will be assessed and calculated using a non-invasive, inert gas re-breathing technique whereby expired gases will be sampled and analysed alongside and blood pressure measurements.

Intervention type: OTHER
Intervention: Echocardiogram
Description: optional (for non-IST participants only)
Study: NCT04203563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong People Strength Training
Description: A community-based progressive strength training program

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Strong People Strength Training
Description: A community-based progressive strength training program
Study: NCT01666678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY98-7111
Description: 2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium (Aleve, BAYH6689)
Description: 2 x Naproxen Sodium 220 mg under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine HCl
Description: 2 x Diphenhydramine HCl 25 mg under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY98-7111
Description: 2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fed conditions
Study: NCT02281903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The TrueCPR feedback device
Description: feedback devices

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard BLS
Description: Standard basic life support = chest compressions without any feedback device (manual resuscitation)
Study: NCT03896880

Intervention type: DIAGNOSTIC_TEST
Intervention: blood culture
Description: During the febrile episode, two blood samples per patient will draw from two separate sites including central venous catheter if present and directly injected to Bact/Alert® bottles and incubated in Bact/ALERT system instrument (bioMérieux Diagnostics, Lyon, France).~A-Identification of microorganisms including:~1. Isolation of microorganisms:~2. Blood culture samples with positive signals will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates.~B-Identification of the bacterial organism~Pure colonies of isolated microorganisms were identified by:~Morphology on agar,Gram stain film was made from the growth to identify morphology of the organism ,Biochemical tests~C-For fungi isolate the following will perform:~1. Microscopic examination of Lactophenol cotton blue (LCB) wet mounts.~2. Culture on Brilliance Candida differential agar

Intervention type: OTHER
Intervention: Anti fungal susceptibility testing or antibiotic susceptibility testing
Description: isolation of microbes from positive blood culture and anti fungal susceptibility testing or antibiotic susceptibility testing according to isolated microbes by disc diffusion method and Vitek2

Intervention type: OTHER
Intervention: phenotypic identification methods of the isolated organism by Vitek2 (BioMerieux,France)
Description: The VITEK 2 is an automated microbial identification system that utilizing growth-based technology. With its colorimetric reagent cards, the VITEK 2 offers a state of the art technology platform for phenotypic identification methods.

Intervention type: OTHER
Intervention: Identification of the isolated organism by multiplex PCR
Description: FilmArray blood culture identification (BCID) is automated multiplex PCR assay, the FilmArray blood culture identification which directly identifies common pathogens, including 7 genera/ species of Gram-positive bacteria, 10 genera/species of Gram-negative bacteria, and 5 species of Candida (as well as 3 resistance determinants) in the positive blood culture bottles. The assay requires about 2 min of hands-on sample processing time and 1 h of instrument time (which includes DNA isolation, amplification, and detection).
Study: NCT03236428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab is a drug that may kill or stop cancer cells from growing through a variety of mechanisms by attaching to the CD38 molecule
Study: NCT02292316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gait and cognitive assessments
Description: several tests are given in each domain

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: gait and cognitive assessments
Description: several tests are given in each domain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: routine analyses in rheumatology such blood count and 25OH-D

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: blood sample
Description: routine analyses in rheumatology such blood count and 25OH-D

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteodensitometry
Description: Looking for osteoporosis

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: osteodensitometry
Description: Looking for osteoporosis
Study: NCT04597489

Intervention type: PROCEDURE
Intervention: Angiography-only
Description: Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.
Study: NCT02605798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbanovir
Description: 1 tablet contains 400 mg sofosbuvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sovaldi
Description: 1 tablet contains 400 mg sofosbuvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sovaldi
Description: 1 tablet contains 400 mg sofosbuvir